Mannitol: Nursing Drug Guide, Renal Failure Risk & NCLEX Review
IV osmotic diuretic for cerebral edema and elevated intraocular pressure: the bedside priority is renal injury when urine output falls—oliguric AKI can progress to anuria with pulmonary edema, electrolyte catastrophe, and CNS toxicity. Infuse over the ordered duration with in-line filtration, trend osmolarity and BMP, and stop the infusion if creatinine rises or mental status worsens.
Labeling reports irreversible renal failure and reversible oliguric acute kidney injury after large IV mannitol doses—even with normal baseline renal function. Patients who develop anuria while receiving mannitol are at risk of congestive heart failure, pulmonary edema, hypertensive crisis, coma, and death. CNS toxicity (confusion, lethargy, coma) may occur with hyperosmolarity or severe hyponatremia. Discontinue OSMITROL if renal function worsens, urine output falls, or CNS toxicity develops.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every infusion, confirm renal, cardiac, and pulmonary status and review the latest basic metabolic panel, serum osmolarity trend, and hourly urinary output. Hold mannitol for anuria, falling urine output, worsening creatinine, or new confusion—then notify the prescriber or pharmacist. Use high-alert medication administration practices for concentration and rate verification.
Most common brand names
Osmitrol is the Baxter brand for mannitol injection in 10%, 15%, and 20% concentrations. Generic mannitol injection is widely stocked in critical care and perioperative areas. Verify concentration on every bag—10%, 15%, and 20% solutions are not interchangeable without prescriber and pharmacy recalculation.
Why we give it — Indications
U.S. prescribing information (OSMITROL) lists mannitol as an osmotic diuretic for reduction of intracranial pressure and treatment of cerebral edema (for example after concussion, hemorrhagic stroke, or other causes of brain swelling per prescriber plan) and for reduction of elevated intraocular pressure (for example perioperative management in glaucoma).
| Use | Detail |
|---|---|
| Cerebral edema / raised ICP | Osmotic reduction of intracranial pressure; requires neurologic monitoring and serial osmolarity/electrolyte checks |
| Elevated intraocular pressure | Single-dose regimen before ophthalmic surgery per labeling; give 60–90 minutes pre-op when used preoperatively |
On a small screen, swipe or scroll sideways to see the full table.
Older texts describe mannitol for oliguric renal failure; that indication was removed from current OSMITROL labeling (2018 revision). Follow the active prescriber order and current product label only.
How it works
Mannitol is a small-molecule sugar alcohol largely confined to the extracellular space. IV administration raises extracellular osmolarity, drawing water from intracellular compartments—including brain parenchyma and aqueous humor—into the vascular space, then enhancing renal excretion of sodium, chloride, and water. Nurses should expect brisk diuresis, shifting sodium and potassium, rising serum osmolarity, and the potential for hypovolemia or hypervolemia depending on renal clearance.
Dosing overview
Individualize total dosage, concentration, and infusion rate to age, weight, fluid requirements, electrolyte balance, serum osmolality, urinary output, and concomitant therapy. Evaluate renal, cardiac, and pulmonary status and correct fluid and electrolyte imbalances before each administration per labeling.
Renal impairment: Patients with pre-existing renal disease or nephrotoxic co-therapy are at increased risk of renal failure; evaluate status before dosing and discontinue if renal function worsens.
Missed dose: Not specified in the reviewed prescribing information; follow prescriber or pharmacy guidance.
Onset, peak, and duration
- Distribution: Largely extracellular; distributes over about 20–40 minutes after IV administration
- Elimination: Primarily unchanged in urine; ~80% of dose excreted within about 3 hours in subjects with normal renal function
- Half-life: Approximately 0.5–2.5 hours with normal renal function; prolonged with renal impairment
- Rebound ICP: Labeling notes a rebound increase in intracranial pressure may occur several hours after infusion—especially with compromised blood–brain barrier
Before you give it — Safety check
Pretreatment checks
- Renal, cardiac, and pulmonary assessment; correct fluid and electrolyte imbalances
- Latest BMP, serum osmolarity, osmol gap, creatinine, BUN, and urine output trend
- Confirm patient is not in anuria or severe hypovolemia
- Screen for active intracranial bleeding (contraindicated except during craniotomy) and pulmonary edema
- Review nephrotoxic and neurotoxic drugs (e.g., gentamicin), other diuretics (e.g., furosemide), and digoxin
Contraindications
- Known hypersensitivity to mannitol
- Anuria
- Severe hypovolemia
- Pre-existing severe pulmonary vascular congestion or pulmonary edema
- Active intracranial bleeding except during craniotomy
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Nephrotoxic drugs (e.g., aminoglycosides, cyclosporine) | Increased risk of renal failure | Avoid concomitant use when possible; trend creatinine and urine output closely |
| Other diuretics | May potentiate renal toxicity | Coordinate with pharmacy; do not assume dual diuresis is safe without orders |
| Digoxin / QT-prolonging drugs | Electrolyte shifts may precipitate cardiac adverse reactions | Monitor potassium and rhythm; discontinue mannitol if cardiac status worsens |
| Lithium | Initial increased elimination may later increase toxicity if hypovolemia or renal impairment develops | Consider holding lithium during mannitol per labeling; monitor levels if co-administered |
On a small screen, swipe or scroll sideways to see the full table.
Administration
- Route: IV infusion preferably into a large central vein; concentrations ≥10% may irritate peripheral veins
- ICP dose: 0.25 g/kg infused over 30 minutes (not a bolus push unless explicitly ordered and supported by policy)
- Intraocular dose: 1.5–2 g/kg over at least 30 minutes as a single dose
- Use administration sets with a final in-line filter; inspect for crystals and warm/re-dissolve per labeling if needed
- Do not administer simultaneously with blood products through the same set (pseudoagglutination/hemolysis risk)
- Do not admix with other medications; use IV infusion pump setup to control rate and document total volume
Hypertonic mannitol extravasation can cause phlebitis, severe pain, and compartment syndrome. Prefer central access for 10% and higher concentrations, assess the site frequently, and stop the infusion for swelling, pallor, or pain.
Expected therapeutic response
- Increased urine output within the diuretic window when renal function permits clearance
- Clinical improvement in signs of raised intracranial pressure or intraocular pressure per prescriber targets (neurologic exam, ICP monitoring, ophthalmic pressures)
- Serum osmolarity rise within expected range without progressive hyponatremia or neurologic decline
Red flags — Stop and act
Renal and neurologic deterioration can escalate within one infusion cycle when urine output does not keep pace with osmotic load.
- Oliguria or anuria during or after infusion—labeling requires discontinuation if renal function worsens
- Rising creatinine/BUN, falling urine output, or osmotic nephrosis concern
- New or worsening altered mental status, lethargy, or coma—CNS toxicity
- Severe hyponatremia, seizures, or headache with neurologic change (hyponatremic encephalopathy risk per labeling)
- Shortness of breath, crackles, or pulmonary edema—especially if anuria develops
- Extravasation, compartment syndrome signs, or anaphylaxis during infusion—stop immediately
Adverse effects
| Adverse effect | Notes (labeling) | Nursing response |
|---|---|---|
| Renal failure / AKI | Oliguria, anuria, osmotic nephrosis, azotemia; may be irreversible | Stop infusion; notify prescriber; strict I&O and nephrology consult per protocol |
| CNS toxicity | Confusion, lethargy, coma, seizures; rebound ICP possible | Discontinue mannitol; neurologic monitoring; repeat BMP and osmolarity |
| Fluid/electrolyte shifts | Hypo/hypervolemia, hyponatremia, hypernatremia, hypo/hyperkalemia | Trend BMP and clinical volume status; hold for dangerous abnormalities |
| Hypersensitivity | Anaphylaxis, hypotension, dyspnea reported | Stop infusion; emergency response per protocol |
| Cardiopulmonary | CHF, pulmonary edema, palpitations | Assess perfusion and respiration; escalate if anuria complicates volume overload |
| Infusion-site reactions | Phlebitis; compartment syndrome with extravasation | Central line when possible; frequent site checks |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Signs of overdose include renal failure, hypo/hypervolemia, hyperosmolarity, electrolyte imbalances, and CNS toxicity (including coma and seizures)—some fatal per labeling.
Antidote
Not specified in the reviewed prescribing information — no specific reversing agent is listed. Management is supportive.
Management per labeling
- Discontinue the infusion and correct fluid and electrolyte imbalances with close monitoring of renal, cardiac, and pulmonary systems
- Mannitol is dialyzable (hemodialysis and peritoneal dialysis); hemodialysis may increase elimination
- Contact local poison control or medical toxicology services per facility protocol for significant overdose or instability
Look-alike / sound-alike and error prevention
- Mannitol vs mannitol/sorbitol irrigant — verify indication (systemic IV vs bladder/ureteral irrigation product)
- 10% vs 15% vs 20% bags — independent double-check grams per kilogram math with pharmacy for ICP vs IOP regimens
- g/kg vs total grams — ICP uses 0.25 g/kg; IOP uses 1.5–2 g/kg; never interchange without recalculation
- Bolus push vs 30-minute infusion — labeling specifies infusion duration; rushing delivery increases osmotic injury risk
- Perform medication reconciliation at transitions—mannitol is often episodic in ICU and easy to duplicate
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Crystals in bag | Warm to 70°C with agitation per labeling; cool to body temperature and re-inspect before use |
| Osmolarity target | Follow prescriber/protocol goal—commonly ≤320 mOsm/L in neurocritical care; confirm local policy |
| Lab interference | False-low inorganic phosphorus and false-positive ethylene glycol tests at high mannitol concentrations |
| Blood products | Never run through same administration set as blood products |
| I&O discipline | Pair every infusion with intake and output monitoring and hourly urine goals |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Pre-existing renal disease | Higher risk of renal failure; evaluate and correct imbalances before dosing |
| Older adults | Greater risk of adverse reactions with impaired renal clearance per labeling |
| Pediatrics <2 years | Higher risk of fluid and electrolyte abnormalities; neonates have limited concentrating ability |
| Compromised blood–brain barrier | Rebound ICP and focal/general cerebral edema risk with repeated doses |
| Pregnancy | Mannitol crosses placenta; available data have not identified drug-associated major birth defects—use only if benefit justifies risk |
| Lactation | No human milk data; weigh infant risk vs maternal clinical need |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Serum osmolarity, osmol gap, sodium, potassium, calcium, phosphate, acid–base status
- Creatinine, BUN, and urine output during and after infusion
- Renal, cardiac, and pulmonary function; intracranial pressure when ordered
- Neurologic status for CNS toxicity or rebound ICP
- Infusion site and volume balance with heart failure or acute kidney injury history
Document
- Concentration, total dose (g and g/kg), infusion duration, and access type
- Pre- and post-infusion BMP/osmolarity and urine output response
- Hold parameters triggered and prescriber/pharmacist notifications
- Patient teaching on reporting decreased urination or neurologic changes
Patient teaching
- Mannitol increases urination when kidneys are functioning—report sharply decreased urine output immediately
- Report confusion, severe headache, seizures, trouble breathing, or infusion-site pain/swelling
- Do not adjust IV rate or stop the infusion without the care team unless safety concerns require clamping and immediate nurse notification
- Understand that labs will be checked frequently for sodium, kidney function, and osmolarity
- Family teaching: neurologic changes may reflect electrolyte or osmolar shifts—escalate early
The Hold Rule
Do not start or continue and contact the prescriber/pharmacist when:
- Known mannitol allergy or active hypersensitivity reaction
- Anuria, severe hypovolemia, active intracranial bleeding (outside craniotomy), or pre-existing severe pulmonary edema
- Oliguria or urine output below prescriber/protocol goal during therapy
- Rising creatinine, worsening renal function, or prescriber order to discontinue if renal status declines
- New confusion, lethargy, coma, or seizures suggesting CNS toxicity
- Serum sodium or osmolarity outside protocol limits or symptomatic hypo/hypernatremia
- Extravasation, compartment syndrome signs, or infusion-related anaphylaxis—stop immediately
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Mannitol is not a routine maintenance fluid—it is a high-stakes osmotic load that demands urine output proof and laboratory surveillance every time.
1. Check-before-you-give protocol
- Right patient, concentration (10/15/20%), calculated g/kg dose, infusion time, and line (prefer central for ≥10%)
- Renal and neurologic baseline documented; allergies and contraindications cleared
- Independent double-check of pump rate and total volume with pharmacy when ordered in g/kg
- Confirm in-line filter attached and bag free of crystals/particulates
2. High-alert and safety badge
High osmolarity IV therapy — renal, neurologic, and extravasation risk require pump verification, I&O, and BMP/osmolarity surveillance comparable to institutional high-alert standards3. Clinical workflow: hold and question rules
- If urine output drops after the first hour, pause and clarify before repeating q6–8 h doses
- If serum sodium falls with neurologic change, stop mannitol and escalate—hyponatremic encephalopathy is a medical emergency per labeling
- Question duplicate orders after ICP normalization—rebound ICP can follow repeated infusions
4. Critical teach-back questions
- “What change in urination should you report right away?” (Patient/family should name greatly decreased or absent urine output.)
- “What neurologic symptoms mean we need help now?” (Patient/family should name confusion, severe headache, seizures, or unusual sleepiness.)
5. Care coordination
Pharmacist: g/kg calculations across concentrations, interaction review with aminoglycosides and diuretics, osmolarity targets, and dialysis coordination if toxicity occurs
Prescriber: Notify for anuria, rising creatinine, pulmonary edema, CNS toxicity, refractory ICP, or need to discontinue therapy when renal function worsens
🧠 Quick mental checklist
- Did I evaluate renal, cardiac, and pulmonary status and correct electrolytes first?
- Is urine output adequate for the osmotic load I am about to give?
- Is this 0.25 g/kg over 30 minutes (ICP) — not an accidental bolus?
- What are the latest sodium, osmolarity, and creatinine values?
- Is the infusion site safe, filtered, and free of crystals?
Mannitol NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for mannitol using a neurocritical-care case panel (MAR, labs, I&O, nursing notes), then priority action, cue-recognition SATA, electrolyte trend SATA, matrix urgency sorting, infusion-rate judgment, and overdose cloze—with explicit evaluate outcomes after the team pauses therapy for oliguria.
Select a tab to view MAR, labs, I&O, and nursing note details for this case.
- Mannitol 20% 0.25 g/kg IV — infuse over 30 min q6h — next dose due 1400 (70 kg patient = 17.5 g)
- Gentamicin 5 mg/kg IV q24h — due 1800 per pharmacy (nephrotoxicity caution on chart)
- Digoxin 0.125 mg PO daily — given 0800
- Maintenance 0.9% NaCl at 75 mL/h
- Home furosemide held on admission
- Serum osmolarity 298 → 312 → 318 mOsm/L (institutional ICP goal often ≤320)
- Na+ 142 → 139 → 131 mEq/L; K+ 4.0 → 3.6 mEq/L
- Creatinine 0.9 → 1.4 mg/dL; BUN 18 → 32 mg/dL
- After 0800 mannitol infusion: urine total 110 mL (goal per order ≥30 mL/h)
- Intake 1.2 L (mannitol + maintenance fluids)
- Net positive 1.09 L; mild periorbital edema noted
- 58-year-old with traumatic brain injury post-evacuation; ICP monitor reading improved overnight then rising since 1100
- 1200: patient more somnolent, slow to name objects; pupils equal
- 1300: Foley drained 15 mL in past hour; nurse reviewing tabs before 1400 dose
- Central line in place; last bag 20% mannitol without crystals
Answer key & rationale
Frequently asked questions
What must I check before giving mannitol?
Evaluate renal, cardiac, and pulmonary status and correct fluid and electrolyte imbalances before administration. Review serum osmolarity, sodium, potassium, creatinine, urine output, neurologic status, allergies, and interacting drugs (nephrotoxic agents, other diuretics, digoxin, lithium). Inspect the bag for crystals, use an in-line filter, and confirm IV access is appropriate for hypertonic solution. Verify contraindications including anuria, severe hypovolemia, active intracranial bleeding (except during craniotomy), and severe pulmonary edema.
When should nurses hold mannitol?
Hold for hypersensitivity, anuria, severe hypovolemia, active intracranial bleeding outside craniotomy, or pre-existing severe pulmonary vascular congestion or pulmonary edema. During therapy, discontinue per labeling if renal function worsens, urine output is inadequate, electrolyte or fluid imbalances develop, CNS toxicity appears, or extravasation/compartment syndrome is suspected.
What adverse effects matter most?
Renal failure and oliguric AKI progressing to anuria, CNS toxicity (confusion, lethargy, coma), life-threatening fluid and electrolyte shifts especially hyponatremia, hypersensitivity including anaphylaxis, pulmonary edema when anuria complicates volume overload, and infusion-site injury including compartment syndrome.
What labs and vitals should I monitor?
Track serum osmolarity, osmol gap, electrolytes (sodium, potassium, calcium, phosphate), acid–base status, creatinine, BUN, urine output, intracranial pressure when ordered, neurologic status, blood pressure, and respiratory assessment for pulmonary edema during and after each infusion.
What patient teaching prevents harm?
Teach patients and families to report decreased or absent urination, confusion, severe headache, seizures, breathing difficulty, or infusion-site pain or swelling immediately. Explain that frequent blood work monitors kidney function and sodium while mannitol is used.
Is there an antidote for mannitol overdose?
No specific antidote is listed in the reviewed OSMITROL prescribing information. Stop the infusion, provide supportive correction of fluid and electrolytes with close renal, cardiac, and pulmonary monitoring, and consider dialysis because mannitol is dialyzable. Contact local poison control or medical toxicology services per facility protocol for significant toxicity.
References
- U.S. National Library of Medicine. OSMITROL (mannitol) injection — SPL product labeling. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0d914965-7001-45cb-ba51-d7c5964b05bc
- National Library of Medicine. Mannitol — Drugs and Lactation Database (LactMed). Bookshelf.https://www.ncbi.nlm.nih.gov/books/NBK501922/
- Joint Formulary Committee. Mannitol monograph. BNF (NICE).https://bnf.nice.org.uk/drugs/mannitol/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.